Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $239.92M |
| Gross Profit (TTM) | $213.53M |
| EBITDA | $-199.55M |
| Operating Margin | -68.10% |
| Return on Equity | -117.10% |
| Return on Assets | -31.00% |
| Revenue/Share (TTM) | $3.56 |
| Book Value | $1.50 |
| Price-to-Book | 70.13 |
| Price-to-Sales (TTM) | 29.48 |
| EV/Revenue | 29.21 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 46.90% |
| Shares Outstanding | $68.85M |
| Float | $56.04M |
| % Insiders | 0.70% |
| % Institutions | 114.86% |
Volatility is currently contracting
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.
Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.75 per share a year ago.
Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, according to preliminary data from an ongoing mid-stage study.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RYTM and any ticker you trade — then tracks every position and per-strategy win rate.
